{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:19Z","timestamp":1790790679727,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.berh.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T16:29:37Z","timestamp":1535646577000},"page":"777-796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Th17 cell responses in spondyloarthritis"],"prefix":"10.1016","volume":"31","author":[{"given":"J.S.H.","family":"Gaston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.berh.2018.07.010_bib1","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.berh.2018.07.010_bib3","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/JLB.0109046","article-title":"IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines","volume":"86","author":"Ortega","year":"2009","journal-title":"J\u00a0Leukoc Biol"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals","volume":"31","author":"Martin","year":"2009","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.20061551","article-title":"Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia","volume":"204","author":"Michel","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1172\/JCI38702","article-title":"IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury","volume":"120","author":"Li","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.berh.2018.07.010_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/cmi.2017.39","article-title":"Characterization and biological significance of IL-23-induced neutrophil polarization","volume":"15","author":"Li","year":"2017","journal-title":"Cell Mol Immunol"},{"issue":"7293","key":"10.1016\/j.berh.2018.07.010_bib10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/nature08949","article-title":"Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology","volume":"464","author":"Buonocore","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.berh.2018.07.010_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","article-title":"Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota","volume":"19","author":"Tang","year":"2018","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.immuni.2008.03.001","article-title":"Th17 cell differentiation: the long and winding road","volume":"28","author":"McGeachy","year":"2008","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni1500","article-title":"The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4","volume":"8","author":"Brustle","year":"2007","journal-title":"Nat Immunol"},{"issue":"7253","key":"10.1016\/j.berh.2018.07.010_bib19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08114","article-title":"The AP-1 transcription factor Batf controls T(H)17 differentiation","volume":"460","author":"Schraml","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib20","doi-asserted-by":"crossref","first-page":"17402","DOI":"10.1038\/s41598-017-17597-3","article-title":"The AP-1 transcription factor JunB is required for Th17 cell differentiation","volume":"7","author":"Yamazaki","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2018.07.010_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.berh.2018.07.010_bib23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.berh.2018.07.010_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"issue":"7318","key":"10.1016\/j.berh.2018.07.010_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib27","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"issue":"7191","key":"10.1016\/j.berh.2018.07.010_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06881","article-title":"The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins","volume":"453","author":"Veldhoen","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-[beta] and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.berh.2018.07.010_bib31","first-page":"1903","article-title":"Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor","volume":"205","author":"Cosmi","year":"2008"},{"issue":"8","key":"10.1016\/j.berh.2018.07.010_bib32","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/eji.200940257","article-title":"CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC","volume":"40","author":"Maggi","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib33","first-page":"S272","article-title":"IL-17 stimulates the secretion of pro-inflammatory cytokines by human macrophages","volume":"40","author":"Jovanovic","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.07.010_bib34","first-page":"S120","article-title":"IL-17 promotes cartilage degradation","volume":"39","author":"Lotz","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib35","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T\u00a0cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17 \u2013 a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/ar1478","article-title":"The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models","volume":"7","author":"Lubberts","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/ard.59.7.529","article-title":"Effect of interleukin 17 on proteoglycan degradation in murine knee joints","volume":"59","author":"Dudler","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/art.10173","article-title":"Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein","volume":"46","author":"Bush","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","article-title":"IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis","volume":"167","author":"Lubberts","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib42","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2010.06.001","article-title":"Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells","volume":"32","author":"Wu","year":"2010","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.20062259","article-title":"T\u00a0cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis","volume":"204","author":"Hirota","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib46","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.34423","article-title":"beta-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice","volume":"64","author":"Ruutu","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib47","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","article-title":"Interleukin-23 mediates the intestinal response to microbial beta-1,3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"6194","key":"10.1016\/j.berh.2018.07.010_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/336073a0","article-title":"Positive and negative selection of an antigen receptor on T cells in transgenic mice","volume":"336","author":"Sha","year":"1988","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.berh.2018.07.010_bib50","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23-Dependent gamma\/delta T cells produce Interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2018.07.010_bib51","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1038\/cti.2017.49","article-title":"Progress of genome-wide association studies of ankylosing spondylitis","volume":"6","author":"Li","year":"2017","journal-title":"Clin Transl Immunol"},{"issue":"23","key":"10.1016\/j.berh.2018.07.010_bib52","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses","volume":"108","author":"Sarin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib54","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2018.07.010_bib55","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3899\/jrheum.100146","article-title":"Frequency and phenotype of T helper 17 cells in peripheral blood and synovial fluid of patients with reactive arthritis","volume":"37","author":"Shen","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2018.07.010_bib56","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib57","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib58","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib59","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.berh.2018.07.010_bib61","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20070663","article-title":"Phenotypic and functional features of human Th17 cells","volume":"204","author":"Annunziato","year":"2007","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.berh.2018.07.010_bib62","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1002\/art.21395","article-title":"Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis","volume":"52","author":"Chan","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib63","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib64","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2018.07.010_bib65","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.1073\/pnas.1011736107","article-title":"Endoplasmic reticulum stress-induced transcription factor, CHOP, is crucial for dendritic cell IL-23 expression","volume":"107","author":"Goodall","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/gene.2014.62","article-title":"Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis","volume":"16","author":"Kenna","year":"2015","journal-title":"Gene Immun"},{"issue":"6394","key":"10.1016\/j.berh.2018.07.010_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao4908","article-title":"Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases","volume":"360","author":"Pommier","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib68","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2018.07.010_bib69","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20140678","article-title":"CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22","volume":"211","author":"Longman","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3893","article-title":"Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy","volume":"14","author":"Huppler","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib72","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ni1460","article-title":"Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17","volume":"8","author":"Leibundgut-Landmann","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2018.07.010_bib73","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","article-title":"Anticytokine autoantibody-associated immunodeficiency","volume":"32","author":"Browne","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.berh.2018.07.010_bib74","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.4049\/jimmunol.1500892","article-title":"Characterization of lamprey IL-17 family members and their receptors","volume":"195","author":"Han","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.berh.2018.07.010_bib75","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib77","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib78","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","article-title":"Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort","volume":"57","author":"Yahya","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"11","key":"10.1016\/j.berh.2018.07.010_bib79","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib80","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.berh.2018.07.010_bib81","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib82","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib83","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A\u00a0phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib84","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib85","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib86","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1586\/17512433.2016.1159130","article-title":"A\u00a0meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE)","volume":"9","author":"Qu","year":"2016","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.berh.2018.07.010_bib87","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib88","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.07.010_bib89","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2018.07.010_bib90","series-title":"Apremilast for treating active psoriatic arthritis (TA433)","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"10.1016\/j.berh.2018.07.010_bib91","series-title":"Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)","author":"National Institute for Health and Care Excellence","year":"2017"},{"issue":"suppl 10","key":"10.1016\/j.berh.2018.07.010_bib92","article-title":"Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis- results from the enthesial clearance in psoriatic arthritis study [Abstract]","volume":"69","author":"Araujo","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000567","article-title":"Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1","volume":"3","author":"Coates","year":"2017","journal-title":"RMD Open"},{"issue":"10086","key":"10.1016\/j.berh.2018.07.010_bib96","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"suppl 10","key":"10.1016\/j.berh.2018.07.010_bib97","article-title":"Ixekizumab provides sustained improvement in signs and symptoms in patients with active psoriatic arthritis: two year results from a phase 3 trial [abstract]","volume":"69","author":"Helliwell","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.berh.2018.07.010_bib98","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to TNF inhibitors: 52-week results from a phase 3 study [abstract]","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib99","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"14","key":"10.1016\/j.berh.2018.07.010_bib100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.07.010_bib101","series-title":"European Medicines Agency cosentyx","author":"European Medicines Agency","year":"2015"},{"issue":"52","key":"10.1016\/j.berh.2018.07.010_bib102","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib103","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40744-017-0076-0","article-title":"A\u00a0review of the use of secukinumab for psoriatic arthritis","volume":"4","author":"Patel","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2018.07.010_bib106","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2018.07.010_bib108","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9906","key":"10.1016\/j.berh.2018.07.010_bib109","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"26","key":"10.1016\/j.berh.2018.07.010_bib110","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2018.07.010_bib111","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib112","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib113","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.23233","article-title":"Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study","volume":"69","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2018.07.010_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2018.07.010_bib115","first-page":"1","article-title":"A\u00a0systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis","author":"Bilal","year":"2018","journal-title":"J\u00a0Dermatol Treat"},{"issue":"14","key":"10.1016\/j.berh.2018.07.010_bib116","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib117","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the treatment of psoriasis: a review of phase III trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib120","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A\u00a0randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2018.07.010_bib121","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjd.14965","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","article-title":"Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab","volume":"8","author":"Spindeldreher","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2018.07.010_bib123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2018.01.003","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab non-responders with plaque psoriasis: a multicenter retrospective study of interleukin (IL)-17A antagonist therapies","volume":"79","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2018.07.010_bib124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2018.07.010_bib125","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.jaad.2016.05.049","article-title":"Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks","volume":"75","author":"Huang","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.berh.2018.07.010_bib126","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaad.2017.11.036","article-title":"Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study","volume":"78","author":"Georgakopoulos","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.berh.2018.07.010_bib127","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"Suppl 10","key":"10.1016\/j.berh.2018.07.010_bib128","article-title":"No increased risk of inflammatory bowel disease among secukinumab-treated patients with moderate to severe psoriasis, psoriatic arthritis, or ankylosing spondylitis: data from 14 phase 2 and phase 3 clinical studies [abstract]","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2018.07.010_bib129","first-page":"1287","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdova","year":"2016","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.berh.2018.07.010_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int J Mol Sci"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:18:59Z","timestamp":1751825939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218300354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1521694218300354"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.07.010","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th17 cell responses in spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}